The potential effects of such inhibition were shown in a study in a dog thrombosis model, in which treatment with the selective P2Y12 antagonist AR-C69931MX (4 μg/(kg·min)) resulted in decreased reocclusion and cyclic flow variation and improved myocardial flow compared with placebo in animals receiving tissue-type plasminogen activator and heparin after thrombus formation [41]. The gene discussed is PLAT; the disease is deep vein thrombosis.